319 related articles for article (PubMed ID: 24638267)
21. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
[TBL] [Abstract][Full Text] [Related]
22. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
23. [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Qian W; Zhu G; Ji Q; Guo Y; Wang Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):217-22. PubMed ID: 24785284
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
Ang KK; Zhang Q; Rosenthal DI; Nguyen-Tan PF; Sherman EJ; Weber RS; Galvin JM; Bonner JA; Harris J; El-Naggar AK; Gillison ML; Jordan RC; Konski AA; Thorstad WL; Trotti A; Beitler JJ; Garden AS; Spanos WJ; Yom SS; Axelrod RS
J Clin Oncol; 2014 Sep; 32(27):2940-50. PubMed ID: 25154822
[TBL] [Abstract][Full Text] [Related]
25. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
[TBL] [Abstract][Full Text] [Related]
26. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
27. Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.
Haussmann J; Tamaskovics B; Bölke E; Djiepmo-Njanang FJ; Kammers K; Corradini S; Hautmann M; Ghadjar P; Maas K; Schuler PJ; Hoffmann TK; Lammering G; Budach W; Matuschek C
Strahlenther Onkol; 2019 Dec; 195(12):1041-1049. PubMed ID: 31586229
[TBL] [Abstract][Full Text] [Related]
28. Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab.
Heiduschka G; Grah A; Oberndorfer F; Seemann R; Kranz A; Kornek G; Wrba F; Thurnher D; Selzer E
Strahlenther Onkol; 2014 Sep; 190(9):832-8. PubMed ID: 24715244
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.
Wu X; Huang J; Liu L; Li H; Li P; Zhang J; Xie L
Medicine (Baltimore); 2016 Sep; 95(39):e4926. PubMed ID: 27684830
[TBL] [Abstract][Full Text] [Related]
30. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
31. nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Adkins D; Ley J; Michel L; Wildes TM; Thorstad W; Gay HA; Daly M; Rich J; Paniello R; Uppaluri R; Jackson R; Trinkaus K; Nussenbaum B
Oral Oncol; 2016 Oct; 61():1-7. PubMed ID: 27688097
[TBL] [Abstract][Full Text] [Related]
32. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050
[TBL] [Abstract][Full Text] [Related]
33. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity.
Rades D; Ulbricht T; Hakim SG; Schild SE
Strahlenther Onkol; 2012 Jan; 188(1):42-8. PubMed ID: 22194029
[TBL] [Abstract][Full Text] [Related]
36. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
[TBL] [Abstract][Full Text] [Related]
37. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
38. Chemoradiotherapy with high-dose cisplatin compared with weekly cisplatin for locally advanced head and neck squamous cell carcinoma.
Hughes RT; Porosnicu M; Levine BJ; Lycan TW; Shenker RF; Frizzell BA; Greven KM
J Med Imaging Radiat Oncol; 2021 Oct; 65(6):796-805. PubMed ID: 34309212
[TBL] [Abstract][Full Text] [Related]
39. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
